What is the global market size of Multiple Myeloma Market?

Global Multiple Myeloma Market size was valued at USD 23.53 billion in 2021 and is poised to grow from USD 25.06 billion in 2022 to USD 44.17 billion by 2030, growing at a CAGR of 6.5% in the forecast period (2023-2030).

Who are the key vendors in the Global Multiple Myeloma Market?

The global Multiple myeloma market is highly competitive. As a result, the global Multiple myeloma market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi', 'Novartis AG', 'Takeda Pharmaceutical Company Limited', 'Celgene Corporation (a subsidiary of Bristol-Myers Squibb)', 'Amgen Inc.', 'Johnson & Johnson', 'AbbVie Inc.', 'GlaxoSmithKline plc', 'Pfizer Inc.', 'Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson)', 'Bristol-Myers Squibb Company', 'Merck & Co., Inc.', 'Onyx Pharmaceuticals (a subsidiary of Amgen Inc.)', 'Millennium Pharmaceuticals (a subsidiary of Takeda Pharmaceutical Company Limited)', 'Spectrum Pharmaceuticals, Inc.', 'Karyopharm Therapeutics Inc.', 'Genmab A/S', 'Servier Pharmaceuticals LLC', 'AbbVie Biotechnology Ltd. (a subsidiary of AbbVie Inc.)', 'Janssen-Cilag International N.V. (a subsidiary of Johnson & Johnson)'

What is the key driver of Global Multiple Myeloma Market?

The use of monoclonal antibodies with a high safety profile to attack myeloma cells. The development of nanomedicine platforms, the increased use of microRNA therapies, and the ongoing development of efficient and safe medications are all contributing to the growth of the multiple myeloma market. When monoclonal antibodies and histone deacetylase (HDAC) inhibitors are added to the current treatment options, the medication market is expected to grow. Clinicians prefer biologic therapy with monoclonal antibodies such as Darzalex and Empliciti due to their well-documented clinical profile.

What is the key market trend for Global Multiple Myeloma Market?

A rise in research and development activities is driving the expansion of the multiple myeloma market. This will present advantageous chances for the expansion of the multiple myeloma market. Along with this, an increase in drug releases and approvals will speed up the market's expansion. The introduction of monoclonal antibodies (mAbs), such as Empliciti and Darzalex, will present a significant growth opportunity for the market because they will not only give patients with multiple myeloma a new therapeutic option, but also increase the interval between relapses, extending the effectiveness of Revlimid and Velcade treatments. These patients will also have access to the second-generation proteasome inhibitors Ninlaro and Kyprolis, broadening their range of treatment options. The market and industry, which are currently under the control of Revlimid, an immunomodulator, and Velcade, a proteasome inhibitor.

Which region accounted for the largest share in Global Multiple Myeloma Market?

Geographically, North America is projected to account for the highest proportion of the global Multiple Myeloma Market for multiple myeloma treatments due to significant growth in the incidence of the disease, high awareness of the need for early cancer detection and treatment, favorable reimbursement policies, and an advanced healthcare system. Due to its quicker approval times, favorable healthcare laws, and concentration of big businesses, Europe has been leading the market for multiple myeloma treatments. Multiple myeloma is more common in developed nations, which is fueling the expansion of the European market.

Multiple Myeloma Companies

Multiple Myeloma Market Competitive Landscape

Multiple Myeloma Market Top Players Company Profiles

Bristol-Myers Squibb Company (US)
Amgen Inc. (US)
Johnson & Johnson (Janssen Pharmaceuticals) (US)
Novartis AG (Switzerland)
Sanofi (France)
Takeda Pharmaceutical Company Limited (Japan)
Pfizer Inc. (US)
Celgene Corporation (Bristol-Myers Squibb Company) (US)
AbbVie Inc. (US)
Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
Karyopharm Therapeutics (US)
Teva Pharmaceutical Industries Ltd. (Israel)
ONO Pharmaceutical Co., Ltd. (Japan)
Merck & Co., Inc. (US)
Eli Lilly and Company (US)
GlaxoSmithKline plc (UK)
Bayer AG (Germany)
Takeda Oncology (Millennium Pharmaceuticals) (Japan)
Oncopeptides AB (Sweden)
Bluebird Bio, Inc. (US)

Multiple Myeloma Market

FAQs

Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).

Multiple myeloma treatment providers should focus on increasing awareness regarding the condition to maximize their business scope going forward. Investing in the research and development of novel multiple myeloma treatments with minimal side effects is also expected to be a key strategy for all market players. Collaborations, mergers, product approvals, new product launches, and acquisitions are slated to be key strategies used by multiple myeloma companies to expand their market presence. 'Bristol-Myers Squibb Company (US) ', 'Amgen Inc. (US) ', 'Johnson & Johnson (Janssen Pharmaceuticals) (US) ', 'Novartis AG (Switzerland) ', 'Sanofi (France) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Pfizer Inc. (US) ', 'Celgene Corporation (Bristol-Myers Squibb Company) (US) ', 'AbbVie Inc. (US) ', 'Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US) ', 'Karyopharm Therapeutics (US) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'ONO Pharmaceutical Co., Ltd. (Japan) ', 'Merck & Co., Inc. (US) ', 'Eli Lilly and Company (US) ', 'GlaxoSmithKline plc (UK) ', 'Bayer AG (Germany) ', 'Takeda Oncology (Millennium Pharmaceuticals) (Japan) ', 'Oncopeptides AB (Sweden) ', 'Bluebird Bio, Inc. (US)'

The senescent population around the world is increasing at a rapid pace and this is slated to be a key factor contributing to high demand for multiple myeloma treatment in the future. Studies show that older adults are more susceptible to multiple myeloma, which in turn is projected to drive the global multiple myeloma market growth over the coming years.

Use of Personalized Medicine: Multiple myeloma treatment companies can focus on the personalized medicine trend as awareness and preference for the same rises among patients around the world. A personalized medicine approach can help multiple myeloma patients improve their chances of successful treatment with less side effects and improved quality of life in the long run.

North America is estimated to secure the top spot when it comes to the multiple myeloma market. Surging incidence of multiple myeloma, high investments in oncology R&D, and growing geriatric population are some key factors that are estimated to aid the dominance of North America in the future. The United States is projected to spearhead the demand for multiple myeloma treatment followed by Canada going forward. High patient awareness regarding symptoms of multiple myeloma, availability of novel treatment therapies and drugs, and shorter approval times for novel therapies are also estimated to aid the dominance of North America in the long run.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Multiple Myeloma Market Competitive Landscape

Multiple Myeloma Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Multiple Myeloma Market Competitive Landscape

Multiple Myeloma Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Multiple Myeloma Market?

Who are the key vendors in the Multiple Myeloma Market?

What is the key driver of Multiple Myeloma Market?

What is the key market trend for Multiple Myeloma Market?

Which region accounted for the largest share in Multiple Myeloma Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300